Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus TACE/TAE in intermediate stage HCC
NCT04268888Phase 3Suspended
- Start
- May 2019
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab in hepatocellular carcinoma (HCC). Started May 2019; status: suspended.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04268888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268888.